팝업레이어 알림

MEDIFIC

is a late preclinical stage biotechnology company developing the MEDIcine of the First-in-Class (MEDIFIC) through deep science and technology for understanding the biology of cancer and cancer stem cells.

Background image

MEDIFIC

is committed to providing better therapeutics by drugging undruggable targets, intrinsically disordered proteins (IDPs) to treat hard-to-treat diseases through open & collaborative innovation.

Background image

MEDIFIC

develops innovative drugs to treat glioblastoma by targeting SREBP, an IDP target for the vulnerability of cancer stem cells, which is the driver of high GBM recurrence.

Background image

VALUES

Translating and Innovating Deep Science into Drug Discovery and Development
for the Treatment of Cancer and Better Life of the Patients.

  • Understanding of
    Deep Science

  • Open Innovation and
    Optimized R&D System

  • Patient and Market-oriented
    Value Creation

  • Better Teamwork and
    Sustainable Growth

MEDIFIC's Keywords

  • Cancer
    Stem Cell
  • First-in-class
  • Targeted
    Protein
    Degradation
  • Exosome
  • Platform
    Technology
  • Targeted
    Therapy

MEDIFIC

Development of first-in-class anticancer drugs for targeting cancer stem cell
Development of exosome-based cancer immunotherapy

CANCER STEM CELL

CSCs have been recognized as a key target
for successful cancer treatment.

VIEW MORE

EXOSOME

Exosomes are valuable therapeutic modality
because of their multiple advantages.

VIEW MORE

PIPELINE

MEDIFIC has core competencies
to meet a variety of unmet medical needs.

VIEW MORE